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Myocardial protection is integral to the functioning of hearts in day to day cardiac surgery. 
However, due to the longer ischaemic times, it becomes pivotal in the management of organs 
during transplantation. There are many different strategies employed to ensure diligent and 
judicious myocardial protection during donor management, transportation of the heart and the 
post-operative period. Given the limited supply of organs and the increasing waiting lists for 
heart transplants worldwide, it has become an area of renewed interest with many innovations 
and inventions using the principles of basic sciences to improve outcomes of transplanted 
hearts. The heart procurement process encompasses several of the different myocardial 
protection strategies in tandem to provide the greatest benefit to the recipients. This review 
looks at the different modalities employed, which include different types of cardioplegia, 
the role of biomarkers, the cutting-edge novel therapies, hormonal therapies and ischaemic 
conditioning strategies.
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INTRODUCTION
Cardiac surgery is a rapidly evolving specialty when 
compared to other forms of surgery. In the 19th century, 
professor Theodor Billroth, one of the pioneers of 
modern abdominal surgery once stated: “A surgeon 
who tries to suture a heart wound deserves to lose the 
esteem of his colleagues” in 1896[1]. In 1951, Russian 
physiologist Vladimar Petrovich Demikhov performed 
the first thoracic transplants recorded. He transplanted 
the heart and lungs of a male dog into a 3-year-old 
female dog. The dog survived 6 days exhibiting normal 
behaviour but succumbed to respiratory complications. 
This was the first recorded history of any animal 
surviving any length of time with a transplanted heart 
supporting its circulation[2].
Stanford University Medical Center led the field in 
cardiac transplantation. Norman Shumway from the 
University of Minnesota was well known for his work 
on myocardial protection. Along with Lillehei, they 
would later lead the team that refined the technique 
of orthotopic heart transplantation. They reported 
a series of orthotopic heart transplantations in dogs 
and perfected a method that had been use previously 
by Cass and Brock by preserving the recipient atrial 
cuffs[3]. They had also first introduced the idea of cold 
cardioplegia. These experiments were successful but 
Shumway that host immunologic mechanisms were 
destroying the graft and survival could be prevented 
by addressing these[4].
Shumway searched for biomarkers to monitor 
transplant rejection. Initial experiments with enzymes 
(hypertensin I) were unsuccessful. He settled on 
electrocardiography as a monitor but noted its 
limitations and pointed out that atrial fibrillation within 
7-21 days of transplant was an early sign of rejection[5]. 
After working with transplant nephrologists, he 
assessed the potential benefits of immunosuppression 
(6-mercaptopurine, azathioprine, and prednisolone) 
and increased survival by up to 250 days in dogs 
receiving orthotopic transplants. Dr. Christiaan Barnard 
extended their pioneering work. Barnard undertook the 
first successful human-to-human heart transplant in 
December 1967[6], before Shumway’s group followed 
shortly afterwards in January 1968.
However, the initial reported 1-year survival was 
only 22%, resulting in most centers abandoning this 
procedure[7]. Shumway’s group at Stanford along 
with other contemporaries (Cabrol’s group at Paris, 
Lower’s group at Virginia) persevered and following 
introduction of cyclosporine, 1-year survival increased 
to approximately 80% by the 80s.
The number of heart transplants performed worldwide 
continued to increase until the shortage of donors 
in the 1990s became a limiting factor[8]. In 2005, 
almost half (48%) of patients had spent at least 2 
years on the heart transplant waiting list worldwide[9] 
leading to challenging decisions about the eligibility 
of donor hearts. Abuanzeh et al.[10] described steps 
utilized by their retrieval team to optimize donors. 
This was included standardizing protocols which 
includes insertion of a pulmonary artery catheter and 
performance of cardiac output studies, weaning other 
vasopressors and commencing arginine vasopressin, 
and administration of hormone replacement. This 
included tri-iodothyronine, methylprednisolone and 
insulin. They managed to retrieve 14 additional hearts 
in that time frame (56% of the borderline hearts) after 
aggressive donor management and optimization[10].
Despite recent advances, myocardial protection 
during heart transplantation remains a challenging 
avenue. With the increasing usage of borderline 
donor hearts as described, we review some of the 
myocardial protection strategies and potential markers 
for perioperative myocardial infarction.
CARDIOPLEGIA
Ringer first noted the relationship between potassium 
and sodium concentration and the heart rate in 
1883[11]. Experimentations with potassium citrate were 
initially unsuccessful due to the excessive osmolality 
due to the high-concentration potassium citrate[12]. 
Most cardioplegic solutions today employ a more 
physiological osmolality and potassium concentration.
Cardioplegic solutions are defined as intracellular and 
extracellular solutions based on the concentrations 
of sodium and potassium ions. Extracellular solutions 
contain high levels of potassium, magnesium and 
sodium, while intracellular solutions contain low 
electrolyte levels. Intracellular solutions mimic the high 
potassium/low sodium conditions reducing potential 
concentration gradients across the plasma membrane, 
thereby halting potassium efflux. This reduction in 
membrane potential resting state prevents generation 
of action potentials. The function of the Na+/K+ 
ATPase channel is reduced in hypothermic conditions, 
therefore permitting the intracellular concentrations 
to persist[13]. Extracellular cardioplegia on the other 
hand works by preventing repolarization of myocytes. 
Potassium rich perfusate in the extracellular space 
reduces the membrane voltage difference causing 
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depolarization. Intracellular calcium sequestration 
occurs via active transport across an ATP-dependent 
pump allowing relaxation of the myocardium in diastole. 
Repolarization however is prevented by the high 
potassium concentration of the cardioplegic solution. 
Both intracellular and extracellular cardioplegic 
solutions have similar long-term outcomes[14].
Norman Shumway first noted the use of topical 
hypothermia to reduce myocardial metabolic 
requirements in 1960 when chemical cardioplegia 
fell out of favour[15]. Denton Cooley then attempted 
intermittent aortic occlusion and utilized Kay’s work 
with intracoronary blood perfusion with cross clamp 
fibrillation[16-18].
Clinical cardioplegia was reintroduced in the 1970s by 
using a low-sodium solution by Bretschneider et al.[19] 
with potassium chloride[20] that was reported as safe 
and allowed safer aortic cross-clamping allowing cold 
crystalloid cardioplegic solutions to be in favour for 
general cardiac surgery. Blood was later introduced 
as medium for cardioplegia by Buckberg as it was 
later discovered that reperfusion injuries occurred 
in crystalloid cardioplegia due to the associated 
influence of calcium and oxygen as described 
by Buckberg[21] and Hearse et al.[22]. There are 
intracellular and extracellular types of crystalloid 
cardioplegia which have become the gold standard 
for cardiac preservation [Table 1][23].
Histidine-tryptophan-ketoglutarate (custodiol/
bretschneider)
Reichenspurner et al.[24] studied the effect of histidine-
tryptophan-ketoglutarate (HTK) in a cohort of 600 
(524 male:76 female) patients undergoing heart 
transplantation over a 10-year period (1981-1991). 
They reported good results provided the ischaemic 
times were less than 4 h.
Sung et al.[25] compared Bretscheinder’s HTK solution 
(18 patients) and cold blood cardioplegia (CBC) (49 
patients) for myocardial protection in donor heart 
preservation. Cold HTK solution was infused at low 
perfusion pressure after procurement and the donor 
heart was placed in a sterile bag containing HTK 
solution. The CBC group heart was placed in St 
Thomas’ Hospital (StH). The heart was covered with 
ice-cold saline for topical cooling and packed in a 
container filled with ice. Two patients (11.1%) in the 
HTK group died within 30 days of surgery due to right 
heart failure and pneumonia with septic shock. There 
were 4 deaths (8.2%) in the CBC group due to acute 
rejection (n = 2), right heart failure and pneumonia 
with septic shock. There was no statistically significant 
difference between thebypass time, ischaemic time 
short term outcomes, creatine kinase/CKMB/troponin 
I values, length of ICU stay, and hospital stay between 
Table 1: Comparison of cardioplegic solutions contents
HTK[15]
University of 
Wisconsin[16]
Celsior[14] Eurocollins[17]
St Thomas’s 
Solution[18]
Intracellular/extracellular Extracellular Intracellular Extracellular Intracellular Extracellular
Na+ 10 25 100 10 120
K+ 10 120 15 115 16
Ca2+ 0.015 0 0.25 0 1.2
Mg2+ 4 5 13 0 16
Cl– 50 20 0 15 160
Glucose – 0 0 180 0
Others a-KG Adenosine 0 0
Glucose 0 0 0 195 0
Impermeant/colloid
  Hydroxyl-Ethyl Starch (g/L) 0 0 50 0 0
  Lactobionate 0 0 100 80 0
  Mannitol 30 0 60 0
  Raffinose 0 0 30 0 0
Buffer
  Phosphate 0 25 0 100 0
  Bicarbonate 0 0 0 10 10
  Histidine 180 0 30 00
  Osmolarity (mOsm/L) 310 330 320 375 320
Anti-oxidants
  Glutothione 0 2 3 0 0
  Allopurinol 0 1 0 0 0
  Tryptophan 2 0 0 0 0
All units expressed in mmol/L unless otherwise indicated
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mortality (46% vs. 42%, P = 0.7) and cause of death 
(chronic rejection: 50% vs. 50%; neoplasia: 33% vs. 
25%, P = 0.8). Survival at 12 years was 50 ± 12% vs. 
52 ± 11% (P = 0.9). Follow-up echocardiogram showed 
similar mean left ventricular ejection fraction (LVEF; 47 
± 12% vs. 49 ± 11%, P = 0.7) and prevalence of LVEF < 
35% (21% vs. 18%, P = 0.8). The prevalence of chronic 
rejection was similar in both groups (42% vs. 32%, P 
= 0.1), but severe allograft vasculopathy was more 
prevalent in the St Thomas cardioplegia group (64% 
vs. 17%, P = 0.04). There were no other between-
group differences[31].
Eurocollins
Collins et al.[32] designed an “intracellular” organ 
preservation solution and is credited to being one 
of the first solutions to attempt the advancement of 
organ preservation based on changes that occur 
during cell hypothermia. The predecessor to the 
Eurocollins solution, Collins solution, provided reliable 
preservation and was the organ preservation fluid of 
choice in abdominal organ transplantation especially 
renal preservation.
Collins solution has a high potassium content alongside 
a glucose osmotic barrier. Despite achieving relatively 
long storage times for abdominal organs, hearts were 
more susceptible to ischaemic injury and the low 
protective properties of glucose compounded by the 
acidotic conditions resulting from glucose conversion 
to lactate resulted in the addition of mannitol or sucrose 
instead of glucose as the impermeant[33]. Euro-Collins 
solution however fell out of favour due to the variability 
of recovery of hearts at non-uniform temperatures[34].
University of Wisconsin (Belzer UW/Viaspan)
University of Wisconsin Solution (UW) was formulated 
by James et al.[35] in the late 1980s as the preservation 
fluid of choice for pancreas preservation. Prior to its 
introduction, abdominal organs preserved in Collins 
solution would have limited ischaemic tolerance of 
about 8 h. Belzer and Southard developed UW solution 
initially to prolong liver and pancreas preservation. 
Their initial experiments of canine pancreases were 
encouraging and used it for liver and kidneys with 
similarly encouraging results[36-38].
UW solution became the “gold standard” of preservation 
fluids as it first highlighted the lack of equilibrium 
achieved by Na+/K+ ratios during cold preservation[39]. 
It contains lactobionate and raffinose, which are 
metabolically inert, making it suitable for multiorgan 
usage. Both these substances which are osmotically 
active prevent organ oedema. Addition of adenosine 
provides precursor of an energy source (ATP). 
the 2 groups. There was however a higher inotropic 
score in the HTK group at 24 h (P = 0.03). Multivariate 
analysis revealed a significantly reduced bypasstime in 
the HTK group (P = 0.002). They concluded that HTK 
was superior due to the reduced pumping time albeit 
with a higher post-operative inotrope score. A single 
dose of HTK provided similar myocardial protection 
as repeated doses of CBC solution in donated hearts. 
Minami et al.[26] noted an increment in troponin and 
CK-MB levels if the ischaemic times were > 4 h using 
HTK solution but concluded that it was still within 
acceptable limits when compared to other crystalloid 
cardioplegias CK-MB 25 IU and troponin I 21 pg/mL, 
with ischaemic time of 263 min).
HTK is an intracellular type of cardioplegic solution. It 
lowers concentrations of sodium and calcium thereby 
inducing cardiac arrest by deprivation of extracellular 
sodium thus preventing depolarisation of the action 
potential. Calcium channels open leading to increased 
cytosolic calcium and potentially aggravating cellular 
injury, indirectly reducing the calcium concentration. 
Histidine in the HTK solution, acts as a buffer enhancing 
the efficiency of anaerobic glycolysis. This has been 
quoted by several sources to be its primary advantage, 
with its buffering capacity allowing effective myocardial 
preservation. The Ketoglutarate (α-KG) component 
serves as a high energy ATP provider during reperfusion. 
Tryptophan stabilises the cell membranes. Mannitol, an 
osmotic diuretic is added to reduce cellular oedema as 
it has free radical scavenging properties thus reducing 
the extent of ischaemic injury[27].
St Thomas’s solution
St Thomas’s solution (StH) is an extracellular type of 
cardioplegic solution that induces rapid cardiac arrest 
by high potassium and magnesium concentrations 
alongside the membrane stabilising effect of 
procaine[28]. Addition of a buffer and reduction of 
calcium concentrations resulted in the formation of 
No. 2 (Plegisol, Abbott Laboratories, North Chicago, 
III.). In a rat model, Plegisol was shown to be superior 
to its predecessor with lower rates of post-operative 
ventricular fibrillation, increased left ventricular 
pressure and recovery of aortic flow[29]. Addition of 
procaine in this solution reduces the incidence of post-
declamping ventricular fibrillation. Luciani et al.[30] group 
performed a prospective single blinded randomised 
control trial comparing cold blood cardioplegia to StH 
(crystalloid cardioplegia). Spontaneous sinus rhythm 
was significantly higher in the blood cardioplegia 
group (11% vs. 40%) (P = 0.02) with a higher creatine 
kinase (P = 0.01) and CK-MB (144 ± 90 IU vs. 102 ± 
59 IU) (P = 0.06). They performed a follow up study 
12 years later and revealed no difference in terms of 
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Allopurinol with glutathione act as antioxidants[40,41]. UW 
limited ischaemic damage from prolonged storage and 
improved myocardial function in the early posttransplant 
period, thus allowing transplantation of organs with 
ischaemic times > 300 min[42]. Jeevanandam et al.[43] 
performed a study comparing University of Wisconsin 
solution with crystalloid cardioplegia to saline storage 
and noted a significant improvement in mean time 
from reperfusion to achieving a stable rhythm, need for 
intraoperative defibrillation, need for cardiac pacing and 
CK-MB release over 48 h. They however also reported 
higher CK-MB levels (335 IU) post-operatively despite 
a relatively shorter ischaemic time of 153 min when 
compared to the HTK group of Minami’s cohort[26].
Celsior
Dr Menasche and colleagues developed Celsior 
solution[44]. They utilised lactobionate and mannitol as 
impermeants. Celsior also uses histidine as a buffer 
and glutamate as an energy substance alongside 
magnesium to stabilise calcium levels. Unlike UW 
which has a high potassium content, Celsior had 
a lower potassium content and a high sodium 
concentration. In canine models, Celsior had a similar 
cardioprotective profile as UW. Higher concentrations 
of potassium results in increase coronary vascular 
resistance secondary to endothelial distension[45,46]. De 
Santo et al.[46] compared the results of “high risk” grafts 
vs. “standard” grafts using Celsior. They followed up 
200 consecutive heart recipients with 73 in the high-
risk group (defined as 2 or more of the following: age 
> 45, female, high pre-retrieval inotropic support, size 
mismatch > 20%, and ischaemia time > 180 min) and 
127 in the standard group. There was no difference 
noted between the two groups in terms of 1-year 
mortality, hospital mortality, histological findings and 
patterns of enzyme release[47].
Comparison of cardioplegic solutions
Lee et al.[48] combined both the intracellular and 
extracellular cardioplegic solutions (HTK and StH). 
In their cohort of 31 patients, they demonstrated non-
inferiority to other approaches. The theoretical benefits 
include the quick initial arrest from StH alongside 
the prolonged effect of HTK alongside its buffering 
mechanism. The effectiveness of HTK has resulted 
in lower CK and lactate dehydrogenase levels in non-
transplant cardiac surgery [Table 2][48,49].
Comparisons between the different crystalloid 
cardioplegia solutions are difficult to extrapolate due to 
the lack of direct comparisons. Several smaller animal 
studies however do suggest potential superiority of 
HTK cardioplegia over the rest.
BIOMARKERS
Cardiac troponins have largely replaced cardiac muscle 
enzymes (CK-MB) for the diagnosis of myocardial 
infarction. Cardiac troponin T (cTnT) and troponin I (cTnI) 
are cardiac regulatory proteins that control the calcium 
mediated interaction between actin and myosin. cTnT 
is also expressed in small amounts in skeletal muscles 
as well. The role of post-operative troponin release as 
a prognostic factor for mid- and short-term all-cause 
mortality after adult cardiac surgery is accepted albeit 
cut-off values are difficult to establish due to the variety 
of timing of the Tn testing, Tn subunit and Tn assays[59]. 
Its prognostic value in a transplant setting however 
has not been clearly understood. CK-MB and troponin 
I are released immediately after transplantation and 
depends on myocardial ischaemic damage, which is 
related to ischaemic time[60].
De Santo et al.[60] investigated troponin release after 
cardiac transplantation. Data from 362 consecutive 
recipients were collated over 11 years. Target outcomes 
included factors determining troponin release, early 
graft failure, rise in creatinine and operative death. 
This study depicted the largest group of adult cardiac 
transplantation patients who had cTnI levels correlated 
with perioperative morbidity and mortality reported in 
the literature thus far. The pattern of troponin release 
observed was similar to that reported by Minami. 
cTnI release > 10 μg/L proved to be an independent 
predictor for early graft dysfunction which in turn 
was a determinant of hospital mortality. Factors that 
predicted this rise included previous cardiac surgery, 
left ventricular hypertrophy, increased ischaemic 
time and transplant status 2B. Troponin proteins are 
intracellular proteins released primarily from cardiac 
myocytes undergoing cellular necrosis. Perhaps 
surprisingly, ischaemia/reperfusion injury following 
cardiac transplantation may not cause cellular necrosis 
and occasionally troponin concentrations may not be 
increased[61].
Brain natriuretic peptide (BNP) is actively synthesized 
and released from cardiac myocytes in response 
to ischaemia and inflammation[62]. It is not directly 
stimulated by surgical manipulation or cardiopulmonary 
bypass, hence its role as a biomarker for ischaemic 
reperfusion injury in non-transplant cardiac surgery to 
predict post-operative dysfunction[63,64]. McIlroy et al.[65] 
studied the role of BNP as marker for myocardial 
ischaemic reperfusion in 25 consecutive patients 
following cardiac transplantation. The median 
preoperative troponin-I concentrations were almost 
three-fold the upper limit of normal in both the donor 
and recipient. The donor BNP levels centred around 
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the upper limit of normal, while in recipients, it was 
the levels were all markedly elevated with greater 
heterogeneity. Posto-peratively, BNP had a moderate 
correlation with ischaemic time (ρ = 0.52, P = 0.01), 
donor BNP (ρ = 0.45, P = 0.03), and donor troponin-I 
(ρ = 0.49, P = 0.01). The post-operative concentrations 
of BNP were significantly higher in patients requiring 
increasing doses of inotropic support. However, there 
was no correlation between post-operative troponin I 
and the measured parameters.
The role of microRNAs (miRNAs) as a biomarker 
for cardiac disease is rapidly expanding due to its 
rapid release kinetics, cardio-selectivity and plasma 
stability[66]. It negatively regulates gene expression by 
prohibiting complementary messenger RNAs (mRNAs) 
translation into functional proteins. Wang et al.[67] 
attempted to monitor initial injury to the myocardium 
and post-operative recovery by detecting levels of 
circulating muscle-specific miRNAs in 7 consecutive 
patients. Fourteen controls were also included in their 
study. Samples were obtained at daily intervals post 
transplantation. They also collected cTnI levels. Their 
results showed significant correlation between miRNAs 
and cTnI (P < 0.05) and the circulating concentrations of 
both proteins were strongly correlated with bypass time. 
Circulating miR-133b correlated well with parameters 
of heart function such as central venous. It also had 
strong correlations with ventilation time (r > 0.99, P < 
0.001) and length of ICU stay (r > 0.92, P < 0.05). They 
Table 2: Comparison of studies comparing cardioplegic agents
Study
Year of 
study
Type Solution Cases (n) Findings Comment
Vega et al.[50] 2001 Open Label RCT
(Humans)
Celsior vs. 
Standard of 
care (UW, 
STh, others)
Celsior (64)
SOC (67)
Fewer patients in the Celsior 
group experienced at least 
one cardiac-related serious 
adverse event
Younger recipients in 
control group
Wieselthaler et al.[51] 1999 Open Label RCT
(Humans)
HTK vs. 
Celsior
HTK (24)
Celsior (24)
Increased Ischaemic time 
for HTK group (P-values not 
given)
2 cases of Acute graft failure 
in HTK cohort
Similar outcomes
Cannata et al.[52] 2012 Retrospective 
cohort (humans)
Celsior vs. 
HTK vs. STh
HTK (61) Celsior 
(38) STh (34)
Similar outcomes Similar outcomes
George et al.[53] 2012 Retrospective 
cohort
UW vs. Celsior UW (42)
Celsior (134)
UW is associated with less 
acute ischaemic necrosis 
(on pathology) than CS
George et al.[54] 2011 Retrospective 
cohort
UW vs. Celsior UW (3,107) Celsior 
(1,803)
In high-risk allografts, 
UW was associated with 
improved survival
UW recipient cohort 
had significantly 
better haemodynamic 
readings pre-
operatively
Kofler et al.[55] 2009 Retrospective 
cohort
(humans)
UW vs. HTK UW (118) HTK 
(222)
UW demonstrated a 
significantly better survival
HTK group was 
derived from historic 
control
Garlicki et al.[56] 1999 Retrospective 
cohort
UW vs. Celsior 
vs. HTK
UW (64)
CEL (28)
HTK (132)
HTK had highest mortality Statistical significance 
uncertain as P-values 
unavailable
Lee et al.[57] 2011 Prospective 
cohort
Lewis donor rat
HTK vs. 
Celsior
NA HTK = Significant reduction 
in serum troponin I & 
creatine phosphokinase
HTK = reduction in 
upregulation of mRNA for 
interleukin-6, intercellular 
adhesion molecule-1, and 
tumor necrosis factor-a, 
fewer infiltrating cells, 
less apoptosis, and less 
phosphorylated adenosine 
monophosphate-activated 
protein kinase
HTK- superior 
protective effects 
against ischemia-
reperfusion in older 
donors
Ackemann et al.[58] 2002 Prospective 
cohort
28 to 35 kg adult 
fox hound dogs
HTK vs. 
Celsior
19 (HTK) vs. 19 
(Celsior)
HTK = more ATP after 8 and 
12 h of ischemia
HTK = better LV 
function, less prone to 
arrhythmic events
NA: not applicable; LV: left ventricular; HTK: histidine-tryptophan-ketoglutarate
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concluded that cardiac muscle specific miRNAs could 
detect early myocardial injury and possibly predict graft 
dysfunction and recovery post-operatively.
NOVEL THERAPIES
The current standard of care for organ preservation of 
hearts post explant is cold preservation (usually in an 
icebox). Perfusion of the heart with cold preservative 
solution is then followed by explantation and storage of 
the heart at 4 °C. The choice of cardioplegic solution is 
primarily based on experience of individual centres. The 
generally acceptable time for cold preservation is about 
4 h with ISHLT data suggesting that ischaemic times > 
6 h associated with primary graft dysfunction[68]. One 
of the contributing factors to primary graft dysfunction 
may be suboptimal organ preservation alongside the 
role of ischaemia reperfusion injury.
Goldsmith et al.[69] group analysed the potential benefits 
of reducing the ischaemic time (IT). They analysed 
survival rates beyond 20 years’ post-transplantation. The 
study showed that median survival post-transplantation 
was between 10-11 years. Every additional hour of donor 
organ IT, conferred a 25% increased risk of death after 
heart transplantation in the first year after transplant, 
with a 5% increase thereafter (P < 0.001). On average, 
recipients surviving a decade post-transplantation could 
potentially gain 0.4 life-years if IT was reduced to 1 h. 
This worked out to almost 3 life years saved if IT was 
reduced to 1 h if someone had IT > 6 h[69].
To overcome this limitation, Hassanein et al.[70] 
proposed the use of a makeshift continuous perfusion 
device to permit prolonged storage of allografts.
At 2 h of reperfusion, the hearts that were continuously 
perfused had higher LV generated pressures and 
lower lactate levels (myocardial acidosis) compared 
to the controls in cold storage. Based on Hassanein’s 
findings, the Organ Care System (OCS), a continuous 
perfusion device developed by TransMedics, Inc., 
Andover, MA, USA, was then used in two phase 1 trials, 
the prospective multi-centre European trial to evaluate 
the safety and performance of the Organ Care System 
for heart transplants (PROTECT) trial based in Europe 
and the Prospective Multicentre Safety and Effective-
ness Evaluation of the Organ Care System Device 
for Heart Use (PROCEED) trial based in the United 
States. The OCS consists of a miniature pulsatile 
pump with an inbuilt inline heater. It is also permits 
monitoring of cardiac output, coronary flow and blood 
pressure via the attached monitor. A specific perfusion 
solution consisting of part crystalloid, part glucose and 
amino acids, physiological extracellular electrolyte 
concentrations, free-radical scavengers, antibiotics, 
and calculated levels of catecholamines and insulin 
alongside oxygenated warm blood with a haematocrit 
of 20-25%; thus simulating a more “physiological” 
environment[71].
The PROTECT trial[72] was a prospective study of 20 
patients who received donor hearts that had been 
maintained by the OCS in a perfused and physiologic 
beating state for a mean time of 3.7 h. The graft 
survival rate of 100% at 30 days and the percentage of 
cardiac related complications was 23%. Additionally, 
OCS was associated with earlier recovery with a 
shorted ventilation time and shorter ICU stay. The 
PROCEED[73] trial was a 20 patient, single arm, non-
randomized, Food and Drug Administration approved 
safety and performance study. This study highlighted 
the importance of lactate concentration during OCS 
use. Hamed’s group concluded that when using the 
OCS for donor heart maintenance, the final serum 
lactate concentrationis the most powerful predictor of 
graft failure post heart transplant with high sensitivity 
and specificity[74].
PROCEED II[75] was the first prospective, open-label, 
multicentre, randomised non-inferiority trial comparing 
OCS to current standard of care (cold hypothermic 
static preservation) at ten heart-transplant centres in 
the USA and Europe. Eligible adult heart-transplant 
candidates were randomly assigned (1:1) to receive 
donor hearts preserved with either the Organ Care 
System or standard cold storage. One hundred and 
thirty patients were recruited and randomised to 
Organ Care System group (n = 67) or the standard 
cold storage group (n = 63). The 30-day patient and 
graft survival rates were 94% (n = 63) in the Organ 
Care System group and 97% (n = 61) in the standard of 
care (P = 0.45). Eight (13%) patients in the Organ Care 
System group and 9 (14%) patients in the standard 
cold storage group had cardiac-related serious 
adverse events. The results were consistent with non-
inferiority of OCS vs. standard of care in terms of short 
term outcomes. Donor hearts in the OCS group had 
a significantly longer preservation (out-of-body) time, 
but shorter cold ischemia time compared to standard 
of care. The longest preservation time with the OCS 
was 9 h and 7 min thought to be due to the extra 
time needed to instrument the donor heart into the 
Organ Care System circuit and optimise the perfusion 
characteristics.
Donation following cardiac death however is a new avenue 
which resulted in an increase of available organs. Initially 
used primarily for kidney transplantation, donor after 
circulatory death (DCD) was first split into four categories 
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by the Maastricht group [Table 3][76].
Of these, type I, II and IV are regarded uncontrolled 
DCD. For these donors, cardiopulmonary resuscitation 
is typically conducted until organ recovery procedures 
are employed.
Iyer et al.[77] conducted a porcine orthotopic heart 
transplant using a DCD asphyxia model. Following 30 min 
of warm ischaemia, the hearts were allocated to 
either OCS preservation of SOC with Celsior solution. 
Following preservation, the OCS group demonstrated 
acceptable lactate profiles and all hearts out of this 
group were successfully transplanted whereas none 
of the hearts in the SOC group could be weaned off 
bypass.
Dhital et al.[78] then piloted the first case series of 
Maastrict group III DCD cardiac transplants at St 
Vincent’s Hospital (Australia) using the OCS. The 
3 recipients (2 men and 1 woman; mean age 52 
years) received the transplants. After periods of 
warm ischaemia < 30 min, ex-vivo perfusion was 
done with the OCS device to resuscitate, assess, 
and transport the donor hearts. Of these patients, 1 
required mechanical circulatory support for 72 h post-
operatively, with all 3 patients showing normal cardiac 
function within a week post-transplantation. Follow up 
data shows patients are still making a good recovery 
at 176, 91, and 77 days after transplantation.The 
cohort included a fourth donor, a trauma victim, who 
was excluded as the warm ischaemic time was > 30 
min (which did not meet the inclusion criteria).
DCD donation however was not pioneered by this group. 
In fact the first ever cardiac transplant by Barnard was 
a DCD heart. Boucek et al.[79] highlighted the first case 
series of DCD donations in the paediatric population 
owing to the higher waiting list mortality compared to 
adults. They successfully performed 3 transplants in 
the paediatric population and found no late deaths (3.5 
years post-operatively) with functional and immunologic 
outcomes similar to those of controls.
In March 2015, the first DCD heart transplant in Europe 
was performed at Papworth Hospital[80]. While it is 
quoted that this may potentially increase the donor pool 
by about 25% in the UK alone, several ethical issues 
arise from DCD heart procurement. These include the 
definition of death. While the needs and feelings of 
the donors and their families are noted, organ viability 
should be maintained and maximized. Organ donation 
in itself should not be the reason for donor death[81].
Another point noted by the Australian group was the 
potential use of OCS for resuscitating marginal donors. 
An estimated 60% of hearts offered are rejected for 
transplantation and the introduction of OCS may 
therefore on paper at least, increase the number of 
suitable organs[82].
HORMONAL THERAPY
As alluded to, the increasing recipient waiting list 
has led to the recruitment of so-called “marginal” 
donors. Brain death usually succeeds a period of 
variable intracranial pressure in which the term 
“coning” is often used. The classic Cushing’s reflex 
of increased blood pressure and reduced heart rate 
is often discernible through monitoring and can lead 
to deleterious effects on multiple organ systems if 
not managed appropriately. There is a compensatory 
arterial hypertension and bradycardia (Cushing’s 
reflex) that is followed by sympathetic stimulation with 
vasoconstriction, raised systemic vascular resistance 
and tachycardia (a triad called the catecholamine 
storm)[83]. There is a redistribution of blood volume that 
prompts visceral ischaemia and in one study, revealed 
that myocardial injury occurs in 20-25% of DBD 
donors[84], with echocardiographic imaging of cardiac 
dysfunction evident in up to 40% of DBD donors[85]. 
Following this catecholamine storm phenomena, there 
is a profound hypotension that results from a reduction 
in sympathetic tone and peripheral vasodilation 
causing mass hypoperfusion of all organs, potentially 
resulting in more organ dysfunction[86].
Cooper et al.[87] and Novitzky et al.[88] noted that 
several animal model studies carried out in South 
Africa in the 1980s demonstrated the catecholamine 
storm phenomena followed by profound hypotension 
occurred with reduction in cortisol, insulin, thyroid, and 
antidiuretic hormone levels, a switch from aerobic to 
anaerobic metabolism and increases in inflammation 
markers and cytokines. Hormonal replacement 
resulted in recovery of cardiac function in both 
experimental animals and humans, thus protecting 
the donor organs. Registry multivariate studies 
on hormonal treatment of brain-dead donors also 
Table 3: Modified Maastricht Classification of DCD[76]
Classification Descriptions
I Dead on arrival and have not been resuscitated
II Unsuccessfully resuscitated
III Typical controlled DCD, with planned cardiac 
arrest
IV Planned DBD that suddenly arrest during or 
after the brain death determination
DCD: donor after circulatory death; DBD: donations following brain 
death
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revealed significant increases in organs transplanted 
and in 1-year survival of kidneys and hearts. Cardiac 
transplant centres then formed specific teams for the 
purpose of “optimizing” the donors with the “Papworth 
Cocktail”[89] of hormones[90]. Multiple studies showed 
increased organ procurement and a reduction in 
primary graft dysfunction in transplanted hearts when 
triple therapy with thyroid hormone, corticosteroids 
and arginine vasopressin was used[91,92].
Cortisol
It has been postulated that haemodynamic instability 
in DBD donors is caused by adrenal insufficiency. 
Nicolas-Robin et al.[93] revealed in their cohort of 
brain-dead patients, adrenal insufficiency was present 
in almost 90%. They also noted that hydrocortisone 
supplementation enhanced systemic haemodynamics 
and decreased norepinephrine dose by more than 
30% in more than half of brain-dead patients with 
haemodynamic instability.
They also identified several pathophysiological groups 
based on cortisol levels and Adrenocorticotropic 
Hormone (ACTH) response. (1) ACTH responders 
with low plasma cortisol: this reflected a hypothalamic-
pituitary failure (secondary adrenal insufficiency) 
resulting from direct insult from intracranial hypertension 
causing ischaemia of the hypothalamus and pituitary 
gland, impairing the release of corticotropin-releasing 
hormone and ACTH as described by Novitzky et al.[94]. 
This group responded to tetracosactrin (synthetic 
ACTH) administration; (2) ACTH non-responders with 
normal baseline cortisol - suggesting primary adrenal 
failure; (3) ACTH non-responders with low baseline 
cortisol: this was probably caused by a hypothalamic-
pituitary-adrenal insufficiency; and (4) ACTH 
responders with normal plasma cortisol: no pathology 
within the hypothalamic-pituitary-adrenal axis.
Ironically, Nicolas-Robin et al.[93]’s study demonstrated 
that hydrocortisone infusion was more often efficient 
in enhancing haemodynamic stability in ACTH non-
responders than in ACTH responders suggesting 
that exogenous steroids have a higher likelihood of 
producing a haemodynamic response when there is 
no endogenous response to ACTH stimulation.
It is also postulated that the effects of corticosteroid 
administration could be due to the re-sensitization of α- 
and β-adrenoceptors pathway which are often altered 
by down-regulation and later by desensitization in 
patients with shock treated with catecholamines[95,96]. 
Another explanation is the “consumption” of cortisol 
following its initial release by the hyper-stimulated 
hypothalamic-pituitary-adrenal axis adrenal gland 
induced by brain death may be unable to replenish 
cortisol stores. Nicolas-Robin et al.[93]’s group also 
noted the effectiveness of hydrocortisone infusion on 
norepinephrine dose decrease was observed in 25% of 
ACTH non-responders with low baseline cortisol. The 
anti-inflammatory properties of hydrocortisone could 
also have an effect as adrenal insufficiency results 
from the release of several cytokines such as tumor 
necrosis factor α, interleukin-1, interleukin-6, and 
overexpression of cell adhesion molecules such as 
intercellular adhesion molecule-1 and E-selectin[97-99].
A French study involving 22 ICUs during 15 months 
to compare two different resuscitation strategies: 
systematic hydrocortisone supplementation (steroid 
group) or no supplementation (control group) in brain-
dead patients who were potential organ donors was 
conducted. Eleven centres administered standard-
care, low-dose hydrocortisone to brain-dead patients 
before organ procurement the remaining 11 did not 
administer corticosteroids[100].
Adrenal insufficiency was noted in almost 80% of 
brain-dead patients. The average number of episodes 
ofhypotension and vascular filling volume per hour were 
similar in the two groups. Although more patients in 
the steroid group received norepinephrine before brain 
death, the mean dose of vasopressor administered 
after brain death was significantly lower than in the 
control group, duration of vasopressor support use 
was shorter than in control group and norepinephrine 
weaning before aortic clamping was more frequent. 
This decrease in number of vasopressors used 
following steroid administration was seen in other 
studies as well[101].
Dhar et al.[102] looked at 132 consecutive brain-dead 
donors managed before and after changing the steroid 
protocol from 15 mg/kg methylprednisolone (high dose) 
to 300 mg hydrocortisone (low dose) and found that 
the only significant differences were lower final insulin 
requirements and faster weaning off insulin infusions 
in the low dose group.
Steroid therapy was not associated with improvements 
in the recovery of primary graft function in these 
studies.
Thyroxine
Another change that occurs with brain death is the 
reduction of plasma-free triiodothyronine (T3) resulting 
in impaired aerobic metabolism. This causes a reduction 
of myocardial energy stores and an increased tissue 
lactate as a result of increased anaerobic metabolism. 
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Novitzky et al.[103] performed one of the pioneering 
studies in the role of T3 in transplants. One hundred 
and sixteen consecutive potential donors were treated, 
alongside 70 recipients with good immediate cardiac 
function in all but 3 patients, who recovered within 24 h 
of mechanical circulatory support. They also conducted 
2 randomized trials in patients undergoing myocardial 
revascularization on cardiopulmonary bypass, and 
administration of post-operative T3 therapy was 
associated with a reduced need for inotropic support and 
diuretic therapy in the first study and improved cardiac 
output in the second study. Chen et al.[104]’s study on 
rat models suggested that T3 can protect myocytes 
against ischemia-induced apoptosis, which may be 
mediated by Akt signalling.
In a study by Jeevanandam et al.[105], donor hearts 
with statistically higher filling pressures, lower EF on 
echocardiograms, and higher inotrope requirements 
were resuscitated with T3 and compared to normal 
donors not receiving T3. All patients survived the 
immediate post-operative period, and at 1 week and 
6 months there were no significant differences in 
systolic blood pressure, diastolic blood pressure, 
heart rate, cardiac index, central venous pressure, 
pulmonary capillary wedge pressure, or LVEF on 
echocardiography. It should also be noted that the 
donors also received furosemide and dopamine, both 
increasing renal perfusion thereby being partially 
responsible for the fall in pre-load and increased mean 
arterial pressure[87].
Novitzky et al.[106] then conducted a retrospective 
review on 63,593 donors (2000-2009) who were 
administered T3/T4. They noted a 12.8% increment 
of organs from T3/T4-treated donors compared to 
untreated donors (P < 0.0001). In study 2, a 15.3% 
increase was noted (P < 0.0001). T3/T4 therapy was 
associated with procurement of significantly greater 
numbers of hearts, lungs, kidneys, pancreases, 
and intestines, but not livers. Multivariate analysis 
indicated a beneficial effect of T3/T4 independent of 
other factors (P < 0.0001)[105]. Apart from Novitzky’s 
work however, there have been mixed reviews on 
the efficacy of T3 administration. A recent systematic 
review conducted by Macdonald et al.[107] noted that 
all case series and retrospective audits reported a 
beneficial effect of thyroid hormone administration 
but all seven randomized controlled trials reported no 
benefit of thyroid hormone administration either alone 
or in combination with other hormonal therapies. In 
four placebo-controlled trials, administration of thyroid 
hormone had no significant effect on donor cardiac 
index (pooled mean difference, 0.15 L/min/m²; 95% 
confidence interval -0.18 to 0.48). They noted that there 
was a lack of consideration of confounding factors in case 
series and retrospective audits. However, it also notes 
that of the few randomized controlled trials conducted, 
the number of patients who were hemodynamically 
unstable or marginal in other ways, who would have 
possibly benefited from T3 administration was too small 
to exclude a benefit of thyroid hormone in this subgroup. 
A randomized trial by Venkateswaran et al.[108] allocated 
80 donors to four treatment groups; A control group, 
T3 monotherapy, Methylprednisolone monotherapy, 
T3 and Methylprednisolone and placebo. Pulmonary 
Artery Catheters were used to guide management, 
with vasopressin infusion commenced while weaning 
catecholamines at the commencement of blinded trial 
medication. The study found no difference in outcomes 
in patients from all 4 groups. They concluded that 
detailed donor haemodynamic measurement and 
management is possibly the most important criteria 
in increasing the yield of transplantable hearts. In 
animal models, administration of T3 was shown to 
improve haemodynamic function before and after 
transplantation[108-110].
However, this has yet to be seen in prospective 
randomized studies in human donors. The stance 
taken by most centres in the UK is to replace T3 only 
when there is evidence of thyroid hypofunction.
Antidiuretic hormone (arginine-vasopressin)
Antidiuretic hormone is synthesized by magnicellular 
neurons at the supraoptic and paraventricular nuclei, 
stored in neurosecretory granules in the axons that 
project into the posterior pituitary[111,112]. Given its 
anatomical location, rising intracranial pressures 
from the Cushing reflex as described earlier plays a 
part in the depletion of ADH. Yoshioka et al.[113] first 
described the role of vasopressin and epinephrine vs. 
epinephrine alone in 16 brain-dead patients improving 
mean survival from 1 day to 23 days. The rise in ICP 
is a cause for neurogenic diabetes insipidus (DI) which 
is very commonly found (in some studies up to 77% 
of solid organ donors[113]), and hormone replacement 
with vasopressin, an effective treatment for DI, would 
have resolved the haemodynamic instability.
Blaine et al.[114] noted that aggressive resuscitation 
with crystalloid solutions may instigate intravascular 
to intracellular fluid shifts thus contribute to the 
development of both interstitial and intracellular oedema, 
and ultimately result in profound hypoperfusion of 
end organs causing the rejection of the organs for 
transplantation. They conducted their study of an animal 
model of a brain-dead organ donor, in which polyuria, 
hypernatremia, and hyperosmolality developed. 
Low-dose (2-10 microU/kg/min) vasopressin was 
continuously infused to maintain plasma sodium and 
osmolality within normal range over the course of the 
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experiments. Cardiovascular function remained stable 
in both control and experimental vasopressin-infusion 
groups, with the only significant difference being a 
moderate rise in pulmonary artery pressure.
Rostron et al.[115] conducted a similar study looking 
at the effects of arginine vasopressin in preventing 
neurogenic vasoplegia which exacerbates lung injury. 
They induced brain death in Wistar rats by inflating an 
intracranial balloon mimicking coning. They noted an 
increment in pulmonary capillary permeability, wet/dry 
lung weight ratios, neutrophil integrin expression and 
pro-inflammatory cytokines in serum (TNF-α, IL-1β, 
CINC-1 and CINC-3), bronchoalveolar lavage (TNF-α, 
IL-1β,) and lung tissue (IL-1β and CINC-1) in braindead 
animals compared to controls. These effects were 
corrected by administration of arginine vasopressin 
(AVP) and norepinephrine to correct the neurogenic 
hypotension.
Another study conducted by Chen et al.[116] investigated 
vasopressin deficiency and hypersensitivity as a 
potential contributing factor to hypotension in organ 
donors. In their cohort of 50 organ donors, 10 patients 
were treated with a continuous infusion of vasopressin 
(0.04 to 0.1 U/min). Mean arterial pressure (MAP), 
catecholamine requirements, serum vasopressin, 
and serum osmolality were obtained before and after 
vasopressin administration. An increment of MAP 
allowed complete discontinuation of catecholamine 
pressors in 40% of patients and a decrement in 
pressor dose in another 40%. Plasma vasopressin 
levels (2.9 ± 0.8 pg/mL) were notably low for the degree 
of hypotension. It is likely that haemodynamically 
unstable organ donors may not only display diabetes 
insipidus but also have a defect in baroreflex-mediated 
secretion of vasopressin, for which supplementation 
would permit catecholamine sparing. The 
catecholamine sparing effects of vasopressin were 
also noted by Pennefather et al.[117] in which 24 DBD 
donors were randomised to receive either saline or low 
dose AVP. The AVP group had a decreased plasma 
hyperosmolality (P < 0.05), improved blood pressure 
(P < 0.01), and reduced inotrope use (P < 0.01), while 
maintaining cardiac output. Myocardial ATP levels 
were higher in the AVP than the control group (NS). 
Kinoshita et al.[118] studied the effects of epinephrine 
and arginine vasopressin in 10 brain dead patients. 
Patients maintained haemodynamic stability for more 
than a week with an initial rise in ST wave changes that 
was reversible. This was confirmed by a normal level 
of CK-MB and normal or slightly swollen mitochondria 
on cardiac biopsy specimens, highlighting the role 
of both arginine vasopressin and epinephrine in 
maintaining haemodynamic stability post brain 
death. Papadopoulos et al.[119] found that vasopressin 
administration reduced the dose of requirements of 
catecholamines and contributed to prevention of the 
post-cardiotomy vasoplegic shock in the patient with 
low ejection fraction (30-40%) on ACE inhibitors in a 
double blind randomized controlled trial whereby the 
group A who were infused with low dose vasopressin 
and the group B who were infused with normal saline 
intraoperatively and for the 4 post-operative hours. 
This further illustrated the benefits of vasopressin out 
with the correction of neurogenic diabetes insipidus.
Glucose-Insulin-Potassium
Calva et al.[120] first conducted experiments on canines 
by inducing myocardial infarctions via coronary artery 
ligation noting the extent of damage to the mitochondria 
with and without glucose-insulin-potassium regimes in 
the 60s. Opie et al.[121] conducted similar studies with 
baboons and noted similar findings, a reduction in 
mitochondrial damage and decreased infarction and 
reduced ST segment depression on EKG. Multiple 
studies have since been done to study the effect 
of glucose-potassium-insulin (GKI) on myocyte 
function. Human studies were first pioneered by 
Sodi-Pallares et al.[122] in which 10 patients with 
acute myocardial infarction and 20 patients with 
chronic coronary insufficiency, with 3 patients showing 
improvements but 2 patients worsening and a general 
improvement in the chronic patients. A meta-analysis 
however revealed no reduction in mortality in patients 
receiving GKI in randomised studies[123]. They concluded 
that while it may have had a potential benefit in the pre-
revascularisation and thrombolysis era, its benefits 
are not clearly evident now. Sun et al.[124] investigated 
the role of GKI for prevention of oxygen free radical 
injury during reperfusion of ischaemic stored hearts. 
Comparing known free radical scavengers (superoxide 
dismustase and catalase) alone and combination 
with GKI in rat models, they noted that there was no 
added benefit of GKI infusion in reduction reperfusion 
injury once reperfusion was commenced, but noted 
an improvement in the superoxide dismustase and 
catalase infusion group. A significant improvement 
however was noted when GKI and the free radical 
scavengers were combined showing improvement in 
left ventricular end-diastolic pressure, myocardial blood 
flow. They concluded that free radical scavengers in 
the presence of glucose-insulin-potassium significantly 
improve functional recovery in the setting of heart 
transplantation.Myocardial dysfunction that occurs 
post brain death is a phenomenon that is ubiquitously 
reported but not fully understood. It is thought to be 
related to direct myocardial injury from sympathetic 
activation[125], potential reduction in oxidative 
metabolism from the reduction in T3, variability 
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of loading conditions, endothelial dysfunction and 
impairment of coronary blood flow[126].
Nicolas-Robin et al.[127] looked at GKI infusion in 
comparison to dobutamine for in DBD donors. They 
found that a GKI infusion significantly improved the 
systolic dysfunction comparably to dobutamine without 
its inherent side effects of peripheral vasodilation, 
potential arrhythmogenesis, and tachycardia. This was 
thought to be possibly due to an adaptive hibernating 
state of the myocardium to reduce myocardial oxygen 
demand, thereby allowing a longer period of ischaemia 
without necrosis[128]. Hence the rationale behind GKI 
infusion is by replenishing the energy supply of the 
failing heart, by switching metabolism from oxidation 
of fatty acids (glycogenolysis) to oxidation of glucose 
(glycolysis) and lactate[129]. This allows restoration of 
calcium homeostasis and replenishment of glycogen 
stores by increasing the rate of ATP[130]. Although GKI 
was not shown to improve mortality in acute myocardial 
infarction as mentioned above, there may be a role for 
it in the ischaemic myocardium.
Cottin et al.[131] demonstrated that their cohort of patients 
with heart failure (Ejection Fraction < 45%), GKI infusion 
reduced Wall Motion Score Index and increased 
ejection fraction significantly in their small study. Similar 
findings were noted in several other studies, including a 
reduction in BNP concentrations[132-135].
ISCHAEMIC CONDITIONING
Reperfusion injury is postulated to be a key 
contributing factor for primary graft dysfunction, thus 
the role of ischaemic conditioning whilst still in its 
trialling phase may be of benefit. The lack of evidence 
of benefit in large scale studies such as RIPheart[136] 
and ERICCA[137] clarified that this intervention does not 
confer any benefits to patients undergoing CABG.
Animal models have shown potential benefits and 
cardioprotective mechanisms, but while biochemical 
improvements were noted by the ERICCA trial 
(reduced troponin levels), its relevance remains to be 
seen. Remote ischaemic preconditioning (RIC) and 
remote ischaemic post conditioning (PostC) work 
on the premise that brief episodes of ischemia and 
reperfusion to the remote organ protect the heart by 
a paracrine or neural-reflex mechanism while avoiding 
additional stress on the heart itself[138].
Thielmann et al.[139] conducted the first single centre 
randomised, double blind controlled trial of RIC in 329 
patients from 2008-2012. They found a significantly 
lower troponin level (cTnI) in the RIC group compared 
to the control group and the all-cause mortality was 
assessed over 1.54 (SD 1.22) years and was lower with 
remote ischaemic preconditioning than without (ratio 
0.27, 95% CI 0.08-0.98, P = 0.046)[137]. Hong et al.[140] 
however failed to demonstrate any difference between 
the groups but it should be noted that he included RIC 
with PostC in 1280 patients and had a much broader 
composite of outcomes. Hong’s group also failed to 
record any biomarkers, limiting the end-points to solely 
clinical outcomes.
Sachdeva et al.[141] noted no subsequent benefit in both 
remote preconditioning and postconditioning alone 
or in combination and observed that they failed to 
attenuate infarct size in an anesthetized rat model with 
myocardial infarction. There was also no recovery of 
LV dysfunction induced by ischemia-reperfusion injury.
However, the recently concluded randomized 
LipsiaConditioning[142] trial studied the effects of RIC 
and PostC revealed conflicting evidence to this. Using 
cardiac magnetic resonance to quantify myocardial 
injury, they showed that combined intra-hospital RIC 
and PostC significantly increases myocardial salvage 
when compared with conventional PCI, whereas PostC 
alone failed to demonstrate a cardioprotective effect in 
STEMI patients undergoing primary PCI.
Another article by Pichot et al.[143] however revealed 
PostC had a significant effect in reducing myocardial 
injury independently of traditional cardiovascular risk 
factors in patients with STEMI.
Ischaemic conditioning has garnered a lot of interest in 
recent times with almost 500 articles published every 
year, and 53 clinical trials (phase I to IV) available 
on PubMed. Of these 37 clinical trials are specific 
to cardiac surgery alone[144]. A lot of the RIC data in 
other studies have focused on biomarkers of cardiac 
injury and not outcomes, which were the endpoints for 
both RIPheart and ERICCA. To date, no adequately 
powered and randomised trial has looked at the effect 
of RIC and PostC in transplantation, and given the 
recent findings of large trials in CABGs, an adequately 
powered trial in transplant cannot be justified. The 
negative results have generated more discussion and 
questions with better discourse into methodology. For 
example, in Kottenberg et al.[145]’s study, propofol was 
a potential confounding factor. Propofol interferes with 
the activation of the signal transducer and activator 
of transcription 5 (STAT5) pathway. A recent study 
by Kleinbongard et al.[146] looking at confounders that 
may affect the efficacy of RIC found that patients 
with an aortic cross-clamp time of < 56 min had no 
protection by RIC whereas there was solid protection 
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by RIC at cross-clamp times of 57-75 min (ratio of RIC/
control = 0.757; P = 0.0348) and of ≥ 76 min (ratio of 
RIC/control = 0.735; P = 0.0277)[146]. RIC theoretically 
confers protection against ischaemia but not trauma 
during surgery (cannulation/handling); thus making 
it plausible that in longer cross-clamp times, the 
protection conferred by RIC becomes more overt due 
to the effect of ischaemic/reperfusion injury. Another 
recent study what studied the effect of preconditioning 
with cyclosporine-A (which prevents MPTP opening 
at the onset of reperfusion, thereby also reducing 
the incidence of ischaemic-reperfusion injury[147] in 
patients undergoing elective CABG revealed similar 
findings, with the cardioprotective benefits noted at 
longer cross-clamp times (85-120 min) but not in the 
shorter (50-85 min) group[148].
Iyer et al.[149] utilised PostC in DCD hearts using a 
porcine asphyxia model and subjected them to warm 
ischaemic times of 20-40 min prior to flushing with 
Celsior solution. The solution was supplemented 
with erythropoietin[150], glyceryl trinitrate[151,152] and 
zoniporide (Cs)[153], a combination that activates 
ischaemic postconditioning pathways.
Hearts were assessed for functional, biochemical and 
metabolic recovery on an ex-vivo working heart apparatus. 
Hearts with postconditioning pathways activated 
demonstrated complete recovery up to 20-min of warm 
ischaemia time after which a rapid decline ensued.
CONCLUSION
There have been multiple recent advances in recent 
times with specific interest in myocardial protection. The 
search for biomarkers however continue to persist and 
may provide a gauge to quantify myocardial damage. 
Continuous normothermic organ perfusion remains an 
interesting prospect that allows transport and working 
assessment of the heart prior to transplantation. This 
has revolutionised DCD transplantation thus added 
more organs to the potential donor pool. Short term 
outcomes of DCD hearts have been good, however long-
term outcomes need to be studied to allow widespread 
use. The role of ischaemic pre- and post-conditioning 
remain uncertain in the field of cardiac transplantation. 
A summation of myocardial protection strategies may be 
the way forward.
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